Skip to main
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics Inc. is showing promising potential due to its focused clinical-stage development of innovative therapies for kidney disease, particularly with the anticipated launch of oxylanthanum carbonate (OLC) in the third quarter of 2026. The company has demonstrated effective management of its development and regulatory strategies, addressing critical issues highlighted by a previous Complete Response Letter (CRL) and now preparing for potential FDA approval. Despite adjustments to financial models and expectations concerning sales and operating expenses, the overall positive outlook is supported by the company's strategic partnerships and ongoing discussions with key payers to secure reimbursement, thereby aiding in the potential commercialization of its product candidates.

Bears say

Unicycive Therapeutics faces considerable risks that could impede its sales potential and negatively impact its valuation, particularly regarding delays in the market launch of oxylanthanum carbonate (OLC) and challenges related to reimbursement and commercial execution. Current market conditions suggest a valuation of $83 million, with projected revenues reaching nearly $625 million by 2031; however, this growth outlook is tempered by concerns over regulatory challenges and execution risks. Additionally, anticipated share dilution from milestone events may artificially suppress the stock price, contributing to an overall negative sentiment regarding its financial outlook.

Unicycive Therapeutics (UNCY) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.